Download MendeleyIdentification of novel quinazolinedione derivatives as ROR gamma t inverse agonist.
Fukase, Y., Sato, A., Tomata, Y., Ochida, A., Kono, M., Yonemori, K., Koga, K., Okui, T., Yamasaki, M., Fujitani, Y., Nakagawa, H., Koyama, R., Nakayama, M., Skene, R., Sang, B.C., Hoffman, I., Shirai, J., Yamamoto, S.(2018) Bioorg Med Chem 26: 721-736
- PubMed: 29342416
- DOI: https://doi.org/10.1016/j.bmc.2017.12.039
- Primary Citation of Related Structures:
6B31 - PubMed Abstract:
Novel small molecules were synthesized and evaluated as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of inflammatory and autoimmune diseases. A hit compound, 1, was discovered by high-throughput screening of our compound library. The structure-activity relationship (SAR) study of compound 1 showed that the introduction of a chlorine group at the 3-position of 4-cyanophenyl moiety increased the potency and a 3-methylpentane-1,5-diamide linker is favorable for the activity. The carbazole moiety of 1 was also optimized; a quinazolinedione derivative 18i suppressed the increase of IL-17A mRNA level in the lymph node of a rat model of experimental autoimmune encephalomyelitis (EAE) upon oral administration. These results indicate that the novel quinazolinedione derivatives have great potential as orally available small-molecule RORγt inverse agonists for the treatment of Th17-driven autoimmune diseases. A U-shaped bioactive conformation of this chemotype with RORγt protein was also observed.
Organizational Affiliation:
Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
